Versatile lipoparticles for the co-delivery of TLR3 and TLR7/8 ligands as vaccine adjuvants: in vitro and in vivo evaluations
Abstract
Recent subunit vaccines based on purified protein antigens have shown reduced immunogenicity and efficacy, highlighting the need for adjuvants to improve the level and quality of the induced immune responses. Toll-like receptors (TLR) are innate immunity receptors that represent promising targets for the development of agonistbased vaccine adjuvants. Combinations of TLR ligands represent an attractive strategy for developing better adjuvants, but remain underexplored due to technical difficulties related to the co-delivery of molecules with distinct physicochemical properties. In this study, we designed LipoParticles based on a polylactic acid (PLA) core with a lipid envelope to co-deliver 3M052, a small molecule agonist of TLR7/8, and Poly (I:C), a synthetic dsRNA that activates TLR3. In vitro, the coordinated activation of the two TLR pathways by these LipoParticles was found more effective than single agonists in stimulating bone marrow-derived macrophages (BMDMs), as evidenced by the increased secretion of several cytokines, such as IL-12p70, TNF-α and IL-1β, and the induction of complementary clusters of immunity gene. Cytokine profiling and transcriptomic analysis also showed that the co-stimulation of TLR3 and TLR7/8 specifically induced inhibitory factors, such as IL-10, IL-19 and IRAK-M. Importantly, following in vivo immunization of mice, the dual formulation appears to modulate the immune profile, with an improved Th1 polarization assessed by quantifying type II IFN secreted by splenocytes, which is a promising finding for vaccine development. Overall, our results validate the efficacy of our LipoParticles as a delivery platform for combinations of TLR ligands. This new carrier will be useful for testing combinations of adjuvant molecules and for selecting those capable of boosting antigen-specific immunity, as this appears to be more complex to achieve than anticipated.
Related
- Plant-Derived Saponin and Polysaccharide Vaccine Adjuvants: Structure-Activity Relationships and Immune-Enhancement Strategies.
- Synthetic adjuvants to potentiate the immune response against rAg85B by nasal route.
- Botanical polysaccharides as veterinary vaccine adjuvants: structure, receptors, and translational limits
- Perceptions of Climate Change Risk and Place Attachment: Parallel Indirect Associations Through In-Visit Evaluations of Memorable Tourism Experience and the Perceived Future Benefits of Edible Insects
- Repurposing amlodipine, fluoxetine, and escitalopram as non-antibiotic adjuvants: in vitro enhancement of ciprofloxacin and fluconazole activity against multidrug-resistant bacterial and candida clinical isolates.
BibTeX
@article{ginet2026versatile,
title = {{Versatile lipoparticles for the co-delivery of TLR3 and TLR7/8 ligands as vaccine adjuvants: in vitro and in vivo evaluations}},
author = {Valentine Ginet and Cynthia Garapon and Céline Coiffier and Jean-Paul Salvi and Camille Ayad and Sophia Djebali and Stéphane Paul and Jérôme Sohier and Pierre-Olivier Vidalain and Bernard Verrier},
journal = {Journal of Controlled Release},
year = {2026},
month = oct,
doi = {10.1016/j.jconrel.2026.115271},
url = {https://hal.science/hal-05785927v1},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Versatile lipoparticles for the co-delivery of TLR3 and TLR7/8 ligands as vaccine adjuvants: in vitro and in vivo evaluations
AU - Valentine Ginet
AU - Cynthia Garapon
AU - Céline Coiffier
AU - Jean-Paul Salvi
AU - Camille Ayad
AU - Sophia Djebali
AU - Stéphane Paul
AU - Jérôme Sohier
AU - Pierre-Olivier Vidalain
AU - Bernard Verrier
PY - 2026
DA - 2026/10/08
JO - Journal of Controlled Release
DO - 10.1016/j.jconrel.2026.115271
UR - https://hal.science/hal-05785927v1
AB - Recent subunit vaccines based on purified protein antigens have shown reduced immunogenicity and efficacy, highlighting the need for adjuvants to improve the level and quality of the induced immune responses. Toll-like receptors (TLR) are innate immunity receptors that represent promising targets for the development of agonistbased vaccine adjuvants. Combinations of TLR ligands represent an attractive strategy for developing better adjuvants, but remain underexplored due to technical difficulties related to the co-delivery of molecules with distinct physicochemical properties. In this study, we designed LipoParticles based on a polylactic acid (PLA) core with a lipid envelope to co-deliver 3M052, a small molecule agonist of TLR7/8, and Poly (I:C), a synthetic dsRNA that activates TLR3. In vitro, the coordinated activation of the two TLR pathways by these LipoParticles was found more effective than single agonists in stimulating bone marrow-derived macrophages (BMDMs), as evidenced by the increased secretion of several cytokines, such as IL-12p70, TNF-α and IL-1β, and the induction of complementary clusters of immunity gene. Cytokine profiling and transcriptomic analysis also showed that the co-stimulation of TLR3 and TLR7/8 specifically induced inhibitory factors, such as IL-10, IL-19 and IRAK-M. Importantly, following in vivo immunization of mice, the dual formulation appears to modulate the immune profile, with an improved Th1 polarization assessed by quantifying type II IFN secreted by splenocytes, which is a promising finding for vaccine development. Overall, our results validate the efficacy of our LipoParticles as a delivery platform for combinations of TLR ligands. This new carrier will be useful for testing combinations of adjuvant molecules and for selecting those capable of boosting antigen-specific immunity, as this appears to be more complex to achieve than anticipated.
SN - 0168-3659
SN - 1873-4995
ER -